GeneLink - Sponsored Study Identifies Genetic Effects Linking Metabolic Syndrome and Altered COQ10 Metabolism
July 14, 2005

MARGATE, NJ – (Business Wire) – July 14, 2005 – GeneLink BioSciences, Inc. (OTCBB:GNLK) is pleased to report that a collaborative study between its scientists and a group led by Dr. Michael Miles at the University of Cincinnati Medical Center and GeneLink using GeneLink’s proprietary genetic technology has identified associations between two genetic variations called SNPs and an altered CoQ10 redox ratio in patients with Metabolic Syndrome.

Metabolic Syndrome is a serious emerging health problem that affects 40 to 50 million American adults. It is related to a constellation of abnormalities that include obesity, abnormal lipid metabolism, and insulin resistance that together yield enhanced risks of cardiovascular problems and Type 2 diabetes mellitus.

The SNPs (single nucleotide polymorphisms) are small genetic variations in DNA that account for much of the person-to-person differences in appearance and physiology. One of the SNPs used in the GeneLink-sponsored study occurs in the gene responsible for the CoQ10 “re-charging” enzyme known as CoQ10 reductase (NQ01). The investigators discovered that individuals with the low activity SNP in NQ01 had a decreased CoQ redox ratio.

This initial study was performed in 52 adults with metabolic syndrome in comparison with 35 healthy controls. The study, entitled “LPL and NQ01 Genotypes are Associated with Decreased Coenzyme Q10 Redox Ratio in Adults with Metabolic Syndrome: An Exploratory Study,” will be presented on July 26th at the International Congress of Clinical Chemistry and American Association for Clinical Chemistry meeting in Orlando, Florida. The annual AACC meeting, which attracts more than 5,000 laboratorians from around the world, is the largest meeting of clinical laboratory scientists.

“Although this is a preliminary study that needs to be validated in a larger cohort, it has important implications not only for understanding the pathophysiology of metabolic syndrome, but also future guidance as to whether CoQ10 in the appropriate dosage and form will be of specific therapeutic benefit to these patients.” said Dr. Harold Harrison, GeneLink’s lead scientist and co-author.

GeneLink’s patent pending SNP test determines whether an individual is able to efficiently recharge CoQ10. People who have the SNP do not convert the CoQ10 as efficiently as those who do not have it.

GeneLink creates and licenses proprietary SNP assessment panels to companies that manufacture or market to the $100 Billion personal care, nutritional supplement and skin care industries. These SNP profile assessments are tools to help companies create and deliver more effective products – personalized wellness and ‘quality of life’ products tailored to their customer’s individual needs – based on the science of genetics. Consumers will no longer be forced to guess what nutritional supplements or skin care products are best for their specific needs. For the first time, simply by swabbing the inside of the mouth with GeneLink’s patented DNA Collection Kit®, consumers can now enjoy the benefits of a tailored nutritional or skin care regimen designed to their individual needs. For more information about GeneLink, visit its website at www.genelink.info.

This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.